RxDoctor Payments Data

Eileen Plotkin, MD

Gastroenterology · New Britain, CTNPI 1346565520

Payments from drug & device makers

$4,507in general payments, 2019–2025

Across 209 payments — averaging $21.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$544
  • Takeda Pharmaceuticals U.S.A., Inc.$470
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$406
  • Madrigal Pharmaceuticals$284
  • Intercept Pharmaceuticals, Inc.$214
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,491100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,507 in reported general payments places this provider in the 55th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$53,255
Medicare patients
210
Services billed
390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab18$120,782
LinzessLinaclotide51$68,624
Dexlansoprazole DrDexlansoprazole40$14,080
SutabSod Sulf/Pot Chloride/Mag Sulf76$12,412
MotegrityPrucalopride Succinate11$11,125
NexiumEsomeprazole Magnesium12$6,075
Lansoprazole37$4,460
Pantoprazole Sodium304$3,509
Sucralfate19$2,093
Ursodiol11$2,036
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates21$1,262
Omeprazole47$965
Famotidine53$910
Esomeprazole Magnesium23$722
Dicyclomine Hcl42$503

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,039$68,62451 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$470$11,12511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in New Britain

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →